TheraRadar
← Back
Data updated: Jun 28, 2026

NOVEL LABS INC

Generics

NOVEL LABS INC is a generic drug manufacturer focused on Infectious Disease, Respiratory, Dermatology.

1985
Since
45
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

NOVEL LABS INC's Key Drugs

NOVEL LABS INC's core commercial portfolio centers on AMLODIPINE BESYLATE AND VALSARTAN, MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Infectious Disease and Respiratory — its most strategically important drugs approved in the last 15 years.

NOVEL LABS INC's Therapeutic Areas

NOVEL LABS INC's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 54%
7 drugs
Respiratory 15%
2 drugs
Dermatology 15%
2 drugs
Gastroenterology 8%
1 drugs
Cardiovascular 8%
1 drugs

NOVEL LABS INC Pipeline Snapshot

Active clinical trials for NOVEL LABS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • AMLODIPINE BESYLATE AND VALSARTAN leads revenue
  • 3 key drugs tracked

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling